Project Grant DP2AI184824
Award Date
8/20/24
Completion Date
7/31/29
Dollars Obligated
$459K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,116 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU) to develop novel 4-aminoquinoline compounds as potential therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest malaria parasite. The project aims to further develop a lead compound, MH02-060, which has demonstrated enhanced metabolic stability and in...
The University of Georgia Research Foundation was awarded a $540,193 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The 12-month award, effective August 22, 2023, supports research to investigate the role of calcium-binding proteins and other secretory pathway components in the exocytosis of organelles critical for the invasion and egress of the malaria parasite Plasmodium falciparum...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $153,056 to support research into heme homeostasis in the malaria parasite Plasmodium falciparum. The research aims to identify and characterize parasite proteins involved in maintaining cytosolic heme concentrations, which is critical for the parasite's survival. The grant was awarded on July 16, 2025 and is set to...
The federal Project Grant award R01AI183533, totaling $813,160.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop mRNA-LNP combination vaccines targeting multiple stages and species of the human malaria parasite, specifically Plasmodium falciparum and Plasmodium vivax. The key objectives are to evaluate the protective efficacy of vaccine antigens targeting...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $700,288 to the University of South Florida to conduct research on the sexual stage development of the malaria parasite Plasmodium falciparum. The project aims to use a functional genomics approach involving random mutagenesis to identify the specific P. falciparum genes essential for the development of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $147,656 to support research aimed at understanding the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The research will integrate biochemical and microscopy approaches to decipher the location and function of these transmembrane proteins within the parasite's...
This $400,347 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to profile malaria parasite lipid biosynthesis and acyl-CoA synthetase activities. The research aims to develop a new "fatty acid alkyne profiling" approach to systematically analyze fatty acid uptake and lipid biosynthesis in Plasmodium falciparum malaria parasites. The project will employ...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $738,445 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Drexel University in Philadelphia, PA. The grant is for a 5-year period from August 1, 2024 to July 31, 2029. The purpose of this grant is to develop an mRNA-based multivalent malaria vaccine that can concurrently drive durable antibody-mediated and cell-mediated protective immune responses against both pre-erythrocytic...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $310,492 to the University of Washington to conduct research aimed at understanding and overcoming immune evasion mechanisms used by Plasmodium parasites that cause malaria. The key objectives are to characterize the memory B cell responses specific to the circumsporozoite protein (CSP) during Plasmodium...
This $791,864 federal Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant's objective is to "Decipher the Role of Non-Coding RNAs in Gene Regulation" related to the Plasmodium falciparum parasite that causes malaria. The research aims to identify molecular factors controlling chromatin organization and gene regulation in the parasite, with a focus on...